Shui He
Guiyang Medical University(CN)Zhengzhou University(CN)Affiliated Hospital of Guizhou Medical University(CN)First Affiliated Hospital of Xi'an Jiaotong University(CN)Weifang University(CN)
Publications by Year
Research Areas
Synthesis and pharmacology of benzodiazepine derivatives, CAR-T cell therapy research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Lymphoma Diagnosis and Treatment, Acute Myeloid Leukemia Research
Most-Cited Works
- → Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera(2015)859 cited
- → Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial(2021)402 cited
- → Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients(2006)395 cited
- → A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea(2013)174 cited
- → A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma(2019)105 cited
- → Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study